- Conditions
- ADHD
- Interventions
- Lidocaine gel
- Drug
- Lead sponsor
- PhenoSolve, LLC
- Industry
- Eligibility
- 7 Years to 49 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Voorhees Township, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 864
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089, Placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 12
- States / cities
- Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Transcranial Direct Current Stimulation
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Physician training
- Behavioral
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- ADHD, Sleep Problems
- Interventions
- Ferrous Sulfate, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
- Interventions
- CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
- Drug
- Lead sponsor
- Cingulate Therapeutics
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 17
- States / cities
- Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465 12.5mg, SHP465 25mg
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- Miami, Florida • Las Vegas, Nevada • Houston, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Active transcranial photobiomodulation, Sham transcranial photobiomodulation
- Device
- Lead sponsor
- Francisco Gonzalez-Lima, PhD
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Attention Deficit Disorder, Attention Deficit Hyerpactivity Disorder
- Interventions
- Highly unsaturated omega-3 fatty acids
- Other
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Posttraumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- RFPP, TFCBT
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 9 Years to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Attention Deficit Hyperactivity Disorder, Substance Abuse
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- ADHD - Inattentive Type, ADHD - Combined Type
- Interventions
- OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- AEVI-001, Placebo
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Wayne, Pennsylvania
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Aptensio XR, Placebo
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Durham, North Carolina
- Conditions
- ADHD
- Interventions
- Behavioral tools integrated within mehealth for ADHD software
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- ADHD, Smoking
- Interventions
- Osmotic-Release Methylphenidate, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 6
- States / cities
- Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- centanafadine capsule, placebo capsule
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 574 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Experimental: methylphenidate treatment
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Attention Deficit Disorder With Hyperactivity, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Interventions
- Vyvanse (lisdexamfetamine dimesylate), NRP104
- Drug
- Lead sponsor
- New River Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • El Centro, California • Irvine, California + 40 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina